Zealand Pharma — Maj 2022
-
Biotek-boss efter frasalg: “I træskolængder får vi formentlig det samme ind som vi har givet”
Salget af produktet V-Go for 10 mio. dollar up-front er nogenlunde samme pris, som selskabet betalte i 2020
Biotek-boss efter frasalg: “I træskolængder får vi formentlig det samme ind som vi har givet”
Salget af produktet V-Go for 10 mio. dollar up-front er nogenlunde samme pris, som selskabet betalte i 2020 Zealand Pharma lagde i marts de kommercielle ambitioner på hylden for at fokusere på at opfi
borsen.dk (borsen.dk)
-
Zealand Pharma banker op på børsen efter frasalg af insulinpumpe
Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.
Zealand Pharma banker op på børsen efter frasalg af insulinpumpe
Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.
(medwatch.dk)
-
Flere spørgsmål til Q&A er meget velkommen.
-
clinicaltrials.gov - May 18, 2022 Drug: Dasiglucagon Phase 3: "A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes" (Not yet recruiting).
-
@exitnu - nogen fornemmelse hvorfor det fine momentum idag?
-
har set dit svar under bava, tak
-
nu går den helt balalejka
-
du er en stjerne tak
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital...
GlobeNewswire News Room (www.globenewswire.com)
-
Dasiglucagon treatment was assessed as well-tolerated in this study and 11 out of 12 patients are continuing into the long-term safety extension study.
These data, together with data from a previously reported Phase 3 study in older children with CHI, are expected to form the basis of a new drug application (NDA) for dasiglucagon treatment in the management of CHI, with the U.S. Food and Drug Administration. Submission is anticipated by end of 2022. -
2 og 4 mest shortede aktier i DKK op 23% og 6% i rødt marked.
-
og os:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind